secwatch.observer — SEC 8-K summary
======================================

Issuer:     BridgeBio Pharma, Inc. (BBIO)
CIK:        0001743881
Form:       8-K
Filed at:   2024-09-11T23:59:59+00:00
Accession:  0001140361-24-040755
Event type: other_material
Sentiment:  negative
Materiality: 0.80
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BridgeBio halts CAH gene therapy after Phase 1/2 shows cortisol production but not transformative; cuts budget $50M+
--------------------------------------------------------------------------------

- Phase 1/2 ADventure trial of BBP-631 in classic CAH: increased endogenous cortisol in all higher-dose patients (max change 6.6 µg/dL post-ACTH); well tolerated with no treatment-related SAEs.
- BBP-631 achieved durable transgene activity: 55-fold avg increase in 11-deoxycortisol at highest doses; ≥50% reduction in 17-OHP in majority of patients.
- Company discontinues BBP-631 development for CAH, citing data not meeting threshold for additional capital investment; budget cut >$50M.
- BridgeBio seeking partnership opportunities for BBP-631 or next-gen CAH gene therapies; est. >75,000 CAH cases in US+EU.
- CFO states reserving gene therapy for priority targets like Canavan disease; will work with FDA to accelerate Canavan therapy.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1743881/000114036124040755/0001140361-24-040755-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1743881/000114036124040755/ef20035749_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-24-040755

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer